Trial Outcomes & Findings for Implementing a Multilevel Intervention to Accelerate Colorectal Cancer Screening and Follow-up (NCT NCT04514341)

NCT ID: NCT04514341

Last Updated: 2026-01-14

Results Overview

The number of patients aged 50-75 years who were up-to-date with colorectal cancer screening during each implementation phase.

Recruitment status

COMPLETED

Target enrollment

4 participants

Primary outcome timeframe

From date of randomization until the last subject completed the study. This could have been up to 36 months.

Results posted on

2026-01-14

Participant Flow

The study recruited four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. Together, these four FQHCs operate 65 primary care clinics and served 131,233 individual patients in 2020. One FQHC from each state was randomly assigned to Group 1, while the remaining two were assigned to Group 2. Both groups received the intervention; the only distinction was that implementation in Group 2 was delayed by three months compared to Group 1.

Unit of analysis: FQHCs

Participant milestones

Participant milestones
Measure
Group 1
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The enrollment number reflects the total number of individual patients seen at each facility (FQHC) during each study phase. Because the study was conducted at the facility level, no individual consent or enrollment occurred. Additionally, the provider and staff education component was conducted at the facility (FQHC) level and did not target individual providers. Therefore, provider characteristics were not assessed at baseline and were not included in the Participant Flow or adverse event reporting. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components, baseline data collection only * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
Group 2
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The enrollment number reflects the total number of individual patients seen at each facility (FQHC) during each study phase. Because the study was conducted at the facility level, no individual consent or enrollment occurred. Additionally, the provider and staff education component was conducted at the facility (FQHC) level and did not target individual providers. Therefore, provider characteristics were not assessed at baseline and were not included in the Participant Flow or adverse event reporting. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components, baseline data collection only * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
Baseline (Months 0-12)
STARTED
18099 2
20834 2
Baseline (Months 0-12)
Group 1 and Group 2 collect baseline data only, no intervention
18099 2
20834 2
Baseline (Months 0-12)
COMPLETED
18099 2
20834 2
Baseline (Months 0-12)
NOT COMPLETED
0 0
0 0
Step 1 (Months 13-18)
STARTED
19318 2
18878 2
Step 1 (Months 13-18)
Both Group 1 and Group 2 receive Component 1 (Provider and Staff Education)
19318 2
18878 2
Step 1 (Months 13-18)
COMPLETED
19318 2
18878 2
Step 1 (Months 13-18)
NOT COMPLETED
0 0
0 0
Step 2 (Months 19-21)
STARTED
21102 2
15725 2
Step 2 (Months 19-21)
Group 1 receives Component 2 (SMS Reminders)
21102 2
0 0
Step 2 (Months 19-21)
COMPLETED
21102 2
0 0
Step 2 (Months 19-21)
NOT COMPLETED
0 0
15725 2
Step 3 (Months 22-30)
STARTED
21102 2
15725 2
Step 3 (Months 22-30)
Both Groups Receive Component 1 and Componet 2
21102 2
15725 2
Step 3 (Months 22-30)
COMPLETED
21102 2
15725 2
Step 3 (Months 22-30)
NOT COMPLETED
0 0
0 0
Step 4 (Months 31-33)
STARTED
21602 2
15037 2
Step 4 (Months 31-33)
Group 1 receives all three components (provider and staff education+SMS Reminders+ Remote PN)
21602 2
0 0
Step 4 (Months 31-33)
COMPLETED
21602 2
0 0
Step 4 (Months 31-33)
NOT COMPLETED
0 0
15037 2
Step 5 (Months 34-45)
STARTED
21602 2
15037 2
Step 5 (Months 34-45)
Both Groups Receive All Three Components
21602 2
15037 2
Step 5 (Months 34-45)
COMPLETED
21602 2
15037 2
Step 5 (Months 34-45)
NOT COMPLETED
0 0
0 0

Reasons for withdrawal

Reasons for withdrawal
Measure
Group 1
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The enrollment number reflects the total number of individual patients seen at each facility (FQHC) during each study phase. Because the study was conducted at the facility level, no individual consent or enrollment occurred. Additionally, the provider and staff education component was conducted at the facility (FQHC) level and did not target individual providers. Therefore, provider characteristics were not assessed at baseline and were not included in the Participant Flow or adverse event reporting. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components, baseline data collection only * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
Group 2
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The enrollment number reflects the total number of individual patients seen at each facility (FQHC) during each study phase. Because the study was conducted at the facility level, no individual consent or enrollment occurred. Additionally, the provider and staff education component was conducted at the facility (FQHC) level and did not target individual providers. Therefore, provider characteristics were not assessed at baseline and were not included in the Participant Flow or adverse event reporting. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components, baseline data collection only * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
Step 2 (Months 19-21)
In a 3-month delay period
0
15725
Step 4 (Months 31-33)
In a 3-month delay period
0
15037

Baseline Characteristics

Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Group 1
n=2 FQHC
The study was conducted at 4 federally qualified health centers (FQHCs): 2 in Illinois and 2 in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components, except that Group 2 began the intervention 3 months later than Group 1. The enrollment number reflects the total number of individual patients seen at each facility (FQHC) during each study phase. Because the study was conducted at the facility level, no individual consent or enrollment occurred. Additionally, the provider and staff education component was conducted at the facility (FQHC) level. Therefore, provider characteristics were not assessed at baseline and were not included in the Participant Flow or adverse event reporting. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components, baseline data collection only * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3 Baseline data collection was restricted to patients aged 50-75 years, the age group eligible for colorectal cancer screening in 2020. While provider and staff education sessions were part of the intervention components, no provider or staff characteristics were collected per protocol.
Group 2
n=2 FQHC
The study was conducted at 4 federally qualified health centers (FQHCs): 2 in Illinois and 2 in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components, except that Group 2 began the intervention 3 months later than Group 1. The enrollment number reflects the total number of individual patients seen at each facility (FQHC) during each study phase. Because the study was conducted at the facility level, no individual consent or enrollment occurred. Additionally, the provider and staff education component was conducted at the facility (FQHC) level. Therefore, provider characteristics were not assessed at baseline and were not included in the Participant Flow or adverse event reporting. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components, baseline data collection only * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3 Baseline data collection was restricted to patients aged 50-75 years, the age group eligible for colorectal cancer screening in 2020. While provider and staff education sessions were part of the intervention components, no provider or staff characteristics were collected per protocol.
Total
n=4 FQHC
Total of all reporting groups
Age, Continuous
FQHC 1
59.25 years
STANDARD_DEVIATION 6.272 • n=8943 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
58.77 years
STANDARD_DEVIATION 6.138 • n=13906 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
58.96 years
STANDARD_DEVIATION 6.195 • n=22849 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Age, Continuous
FQHC 2
60.04 years
STANDARD_DEVIATION 6.374 • n=9156 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
59.45 years
STANDARD_DEVIATION 6.126 • n=6928 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
59.79 years
STANDARD_DEVIATION 6.275 • n=16084 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Sex/Gender, Customized
FQHC 1 · Male
3338 Participants
n=8943 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
5651 Participants
n=13906 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
8989 Participants
n=22849 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Sex/Gender, Customized
FQHC 1 · Female
5019 Participants
n=8943 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
7478 Participants
n=13906 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
12497 Participants
n=22849 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Sex/Gender, Customized
FQHC 1 · Unknown
586 Participants
n=8943 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
777 Participants
n=13906 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
1363 Participants
n=22849 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Sex/Gender, Customized
FQHC 2 · Male
3806 Participants
n=9156 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
2823 Participants
n=6928 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
6629 Participants
n=16084 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Sex/Gender, Customized
FQHC 2 · Female
5345 Participants
n=9156 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
4105 Participants
n=6928 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
9450 Participants
n=16084 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Sex/Gender, Customized
FQHC 2 · Unknown
5 Participants
n=9156 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
0 Participants
n=6928 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
5 Participants
n=16084 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Ethnicity (NIH/OMB)
FQHC 1 · Hispanic or Latino
2811 Participants
n=8943 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
3859 Participants
n=13906 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
6670 Participants
n=22849 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Ethnicity (NIH/OMB)
FQHC 1 · Not Hispanic or Latino
4882 Participants
n=8943 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
8306 Participants
n=13906 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
13188 Participants
n=22849 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Ethnicity (NIH/OMB)
FQHC 1 · Unknown or Not Reported
1250 Participants
n=8943 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
1741 Participants
n=13906 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
2991 Participants
n=22849 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Ethnicity (NIH/OMB)
FQHC 2 · Hispanic or Latino
1295 Participants
n=9156 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
664 Participants
n=6928 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
1959 Participants
n=16084 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Ethnicity (NIH/OMB)
FQHC 2 · Not Hispanic or Latino
4198 Participants
n=9156 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
3316 Participants
n=6928 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
7514 Participants
n=16084 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Ethnicity (NIH/OMB)
FQHC 2 · Unknown or Not Reported
3663 Participants
n=9156 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
2948 Participants
n=6928 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
6611 Participants
n=16084 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Race (NIH/OMB)
FQHC 1 · American Indian or Alaska Native
68 Participants
n=8943 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
616 Participants
n=13906 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
684 Participants
n=22849 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Race (NIH/OMB)
FQHC 1 · Asian
75 Participants
n=8943 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
177 Participants
n=13906 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
252 Participants
n=22849 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Race (NIH/OMB)
FQHC 1 · Native Hawaiian or Other Pacific Islander
34 Participants
n=8943 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
75 Participants
n=13906 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
109 Participants
n=22849 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Race (NIH/OMB)
FQHC 1 · Black or African American
4440 Participants
n=8943 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
5111 Participants
n=13906 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
9551 Participants
n=22849 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Race (NIH/OMB)
FQHC 1 · White
2332 Participants
n=8943 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
4405 Participants
n=13906 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
6737 Participants
n=22849 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Race (NIH/OMB)
FQHC 1 · More than one race
716 Participants
n=8943 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
1636 Participants
n=13906 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
2352 Participants
n=22849 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Race (NIH/OMB)
FQHC 1 · Unknown or Not Reported
1278 Participants
n=8943 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
1886 Participants
n=13906 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
3164 Participants
n=22849 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Race (NIH/OMB)
FQHC 2 · American Indian or Alaska Native
42 Participants
n=9156 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
77 Participants
n=6928 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
119 Participants
n=16084 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Race (NIH/OMB)
FQHC 2 · Asian
66 Participants
n=9156 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
93 Participants
n=6928 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
159 Participants
n=16084 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Race (NIH/OMB)
FQHC 2 · Native Hawaiian or Other Pacific Islander
11 Participants
n=9156 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
28 Participants
n=6928 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
39 Participants
n=16084 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Race (NIH/OMB)
FQHC 2 · Black or African American
1317 Participants
n=9156 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
1699 Participants
n=6928 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
3016 Participants
n=16084 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Race (NIH/OMB)
FQHC 2 · White
7217 Participants
n=9156 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
4366 Participants
n=6928 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
11583 Participants
n=16084 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Race (NIH/OMB)
FQHC 2 · More than one race
193 Participants
n=9156 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
66 Participants
n=6928 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
259 Participants
n=16084 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Race (NIH/OMB)
FQHC 2 · Unknown or Not Reported
310 Participants
n=9156 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
599 Participants
n=6928 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
909 Participants
n=16084 Participants • Patients who were between the ages of 50 and 75 at each FQHC, with FQHC 1 in both groups located in Illinois and FQHC 2 in each group located in Indiana.
Region of Enrollment
United States
18099 participants
n=18099 Participants
20834 participants
n=20834 Participants
38933 participants
n=38933 Participants
Colorectal Cancer (CRC) Screening Up-to-date Rate
FQHC 1: CRC Screening Up to Date
2998 Participants
n=8943 Participants • Number of patients who were between the ages of 50 and 75 and up to date with CRC screening at each FQHC in 2020.
2203 Participants
n=13906 Participants • Number of patients who were between the ages of 50 and 75 and up to date with CRC screening at each FQHC in 2020.
5201 Participants
n=22849 Participants • Number of patients who were between the ages of 50 and 75 and up to date with CRC screening at each FQHC in 2020.
Colorectal Cancer (CRC) Screening Up-to-date Rate
FQHC 2: CRC Screening Up to Date
4639 Participants
n=9156 Participants • Number of patients who were between the ages of 50 and 75 and up to date with CRC screening at each FQHC in 2020.
1817 Participants
n=6928 Participants • Number of patients who were between the ages of 50 and 75 and up to date with CRC screening at each FQHC in 2020.
6456 Participants
n=16084 Participants • Number of patients who were between the ages of 50 and 75 and up to date with CRC screening at each FQHC in 2020.
CRC Order Rate
FQHC 1: CRC Screening Order Rate
1804 Participants
n=6493 Participants • Patients between the ages of 50 and 75 who needed an order for CRC screening at each FQHC in 2020.
3405 Participants
n=12640 Participants • Patients between the ages of 50 and 75 who needed an order for CRC screening at each FQHC in 2020.
5209 Participants
n=19133 Participants • Patients between the ages of 50 and 75 who needed an order for CRC screening at each FQHC in 2020.
CRC Order Rate
FQHC 2: CRC Screening Order Rate
3370 Participants
n=5920 Participants • Patients between the ages of 50 and 75 who needed an order for CRC screening at each FQHC in 2020.
884 Participants
n=5399 Participants • Patients between the ages of 50 and 75 who needed an order for CRC screening at each FQHC in 2020.
4254 Participants
n=11319 Participants • Patients between the ages of 50 and 75 who needed an order for CRC screening at each FQHC in 2020.
CRC Screening Completion Rate
FQHC 1: CRC Screening Completion Rate
711 Participants
n=1804 Participants • Patients between the ages of 50 and 75 who needed CRC screening and received an order for screening at each FQHC in 2020.
1320 Participants
n=3405 Participants • Patients between the ages of 50 and 75 who needed CRC screening and received an order for screening at each FQHC in 2020.
2031 Participants
n=5209 Participants • Patients between the ages of 50 and 75 who needed CRC screening and received an order for screening at each FQHC in 2020.
CRC Screening Completion Rate
FQHC 2: CRC Screening Completion Rate
1672 Participants
n=3370 Participants • Patients between the ages of 50 and 75 who needed CRC screening and received an order for screening at each FQHC in 2020.
344 Participants
n=884 Participants • Patients between the ages of 50 and 75 who needed CRC screening and received an order for screening at each FQHC in 2020.
2016 Participants
n=4254 Participants • Patients between the ages of 50 and 75 who needed CRC screening and received an order for screening at each FQHC in 2020.

PRIMARY outcome

Timeframe: From date of randomization until the last subject completed the study. This could have been up to 36 months.

Population: The overall number represents all participants across all study phases. The number analyzed reflects only participants contributing data at the reported phase.

The number of patients aged 50-75 years who were up-to-date with colorectal cancer screening during each implementation phase.

Outcome measures

Outcome measures
Measure
Group 1
n=62022 Participants
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
Group 2
n=49640 Participants
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
CRC Screening Rate
Phase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation
10720 Participants
3303 Participants
CRC Screening Rate
Phase 1: Provider and Staff Education
8611 Participants
3989 Participants
CRC Screening Rate
Phase 2: Provider Education + Patient Reminder
9438 Participants
3186 Participants

PRIMARY outcome

Timeframe: From date of randomization until the date subject completed the study. This could have been up to 36 months.

Population: The overall number represents all participants who needed screening across all study Phases. The number analyzed reflects only participants contributing data at the reported phase.

The number of patients between the ages of 50 and 75 who needed CRC screening and received a screening order (excluding participants who received an order but have already been up to date with screening ) during each implementation phase.

Outcome measures

Outcome measures
Measure
Group 1
n=41263 Participants
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
Group 2
n=43243 Participants
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
CRC Screening Ordering Rate
Phase 2: Provider and Staff Education + Patient Reminders
6458 Participants
4757 Participants
CRC Screening Ordering Rate
Phase 1: Provide and Staff Education
7012 Participants
5087 Participants
CRC Screening Ordering Rate
Phase 3: Provide and Staff Education + Patient Reminders + Remote Patient Navigation
6478 Participants
4611 Participants

PRIMARY outcome

Timeframe: From date of randomization until the date subject completed the study. This could have been up to 36 months.

Population: The overall number represents all participants who needed CRC screening and received an order across all study phases. The number analyzed reflects only participants contributing data at the reported milestone.

The number of patients between the ages of 50 and 75 who needed CRC screening, received an order for screening, and completed the screening during each implementation phase.

Outcome measures

Outcome measures
Measure
Group 1
n=19948 Participants
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
Group 2
n=14455 Participants
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
CRC Screening Completion Rate
Phase 1: Provider and Staff Educatioin
3106 Participants
1917 Participants
CRC Screening Completion Rate
Phase 2: Provider and Staff Education + Patient Reminders
3031 Participants
1749 Participants
CRC Screening Completion Rate
Phase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation
3278 Participants
1691 Participants

SECONDARY outcome

Timeframe: From the date of the first education session until the completion of the last education sessions. This could have been up to 24 months.

Population: The overall number represents the total number of providers invited to the education sessions during Phase 1 and Phase 2. The number analyzed reflects the number of providers invited to the education sessions during the reported phase.

The number of providers who attended the annual education sessions during Phase 1 and Phase 2. To accommodate the COVID-19 restrictions, all sessions were delivered via Zoom, with multiple sessions scheduled within each FQHC based on clinic availability. Both groups received the education component simultaneously, with no delay in implementation.

Outcome measures

Outcome measures
Measure
Group 1
n=527 Participants
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
Group 2
n=340 Participants
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
Provider Education Participation
Phase 1: Provider and Staff Education
129 Participants
44 Participants
Provider Education Participation
Phase 2: Provider and Staff Education + Patient Reminders
126 Participants
89 Participants

SECONDARY outcome

Timeframe: From the initiation of the SMS reminder system until the last participant enrolled. This could have been up to 30 months.

Population: The overall number represents the total number of participants who received a FIT or colonoscope order during the implementation of Phase 1 and Phase 2. The number analyzed reflects only the number of participants contributing data to the reported milestone.

The number of participants who received a FIT or colonoscopy order (excluding Cologuard, which provides its own reminder services) and subsequently enrolled in the short message service (SMS) reminder system during Phase 2 and Phase 3. The SMS platform was used to engage participants and remind them to complete their screenings; participants could opt out at any time by replying "STOP".

Outcome measures

Outcome measures
Measure
Group 1
n=13013 Participants
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
Group 2
n=10824 Participants
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
Patient Reminder Enrollment
Phase 2: Provider and Staff Education + Patient Reminders
4756 Participants
4693 Participants
Patient Reminder Enrollment
Phase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation
5198 Participants
3943 Participants

SECONDARY outcome

Timeframe: From the navigation service initiated at the partner FQHC until the completion of the study, assessed up to 16 months.

Population: The overall number represents the number of participants whom the navigators successfully contacted and spoke to during Phase 3.

The number of participants who received remote navigation services (phone-based navigation) during Phase 3 and subsequently completed their screenings.

Outcome measures

Outcome measures
Measure
Group 1
n=1330 Participants
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
Group 2
n=1127 Participants
The study was conducted in four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components except that Group 2 began the intervention three months later than Group 1. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3
Impact of Remote Patient Navigation Services
529 Participants
284 Participants

Adverse Events

Group 1 During Phase 0 (No Intervention)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group 2 During Phase 0 (No Intervention)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Groups 1 During Phase 1

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Groups 2 During Phase 1

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group 1 During Phase 2

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group 2 During Phase 2

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group 1 During Phase 3

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Group 2 During Phase 3

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Karen Kim

Penn State College of Medicine

Phone: 7175318326

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place